TACI Antibody and Use Thereof for Detecting Free Drug Levels

The USPTO published patent application US20260098866A1 granting rights to inventors Xuejing Yao et al. for a TACI (Transmembrane Activator and CAML Interactor) antibody with high specificity and affinity. The patent covers: (1) the antibody composition itself, (2) detection methods using the antibody to measure free TACI or TACI-Fc fusion protein levels, and (3) applications for monitoring drug absorption and therapeutic efficacy in autoimmune disease patients.

For pharmaceutical and biotechnology companies developing TACI-Fc fusion protein drugs or therapeutic antibody products, this patent establishes IP rights that may affect freedom to operate. Healthcare providers offering therapeutic drug monitoring services should be aware of potential licensing requirements. Clinical investigators conducting trials on autoimmune disease treatments using TACI-targeted therapies may need to consider IP implications for associated diagnostic methods.